Back

Integrating UHPLC-MS and MALDI-MSI for Spatial Nucleoside Profiling in FFPE Breast Cancer: A Multimodal Molecular Pathology Framework

Wu, J.; Geisberger, S. Y.; Mastrobuoni, G.; Lisek, K.; Raimundo, S.; Nebrich, G.; Grzeski, M.; Rajewsky, N.; Klauschen, F.; Klein, O.; Kempa, S.

2026-01-30 cancer biology
10.64898/2026.01.28.701949 bioRxiv
Show abstract

Formalin-fixed, paraffin-embedded (FFPE) tissues constitute the primary material for diagnostic pathology and retrospective clinical research, yet their use in metabolomics remains limited due to molecular cross-linking and analyte degradation. Here, we establish a cost-efficient molecular pathology workflow that integrates ultra-high-performance liquid chromatography mass spectrometry (UHPLC-MS) with matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) to quantify and spatially map nucleosides in FFPE breast cancer tissues. Optimized extraction using methanol yielded nucleoside profiles comparable to fresh-frozen tissues, while MALDI-MSI enabled the spatial visualization of nine nucleosides across distinct histological regions. Several nucleosides including deoxyadenosine and 5-formylcytosine showed strong discriminatory power between tumor stages, revealing progressive metabolic rewiring during breast cancer progression. Finally, spatial nucleoside patterns observed in a murine model were recapitulated in patient-derived FFPE tissues, underscoring the translational potential of nucleoside-based spatial metabolomics for clinical research and biomarker discovery. Together, this workflow establishes MALDI-MSI as a powerful and scalable spatial molecular pathology tool for interrogating nucleoside biology in archival breast cancer samples. Following MALDI-MSI, the same FFPE tissue sections can undergo laser capture microdissection, enabling genomic, proteomic, or targeted metabolomic profiling of MSI-defined tumor niches and microenvironmental regions. This integration directly links spatial nucleoside signatures to molecular alterations relevant to precision oncology in future.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

1
Nature Communications
4913 papers in training set
Top 13%
12.7%
2
Analytical Chemistry
205 papers in training set
Top 0.3%
8.5%
3
Cancer Research Communications
46 papers in training set
Top 0.1%
4.9%
4
Advanced Science
249 papers in training set
Top 4%
4.4%
5
Molecular & Cellular Proteomics
158 papers in training set
Top 0.6%
4.0%
6
Scientific Reports
3102 papers in training set
Top 33%
3.7%
7
Communications Biology
886 papers in training set
Top 2%
3.6%
8
Genome Medicine
154 papers in training set
Top 3%
3.1%
9
Cell Reports Medicine
140 papers in training set
Top 2%
2.9%
10
Biosensors and Bioelectronics
52 papers in training set
Top 0.5%
2.6%
50% of probability mass above
11
Angewandte Chemie International Edition
81 papers in training set
Top 1%
2.5%
12
EMBO Molecular Medicine
85 papers in training set
Top 1%
2.1%
13
Cell Reports Methods
141 papers in training set
Top 2%
2.1%
14
Laboratory Investigation
13 papers in training set
Top 0.1%
2.1%
15
PLOS ONE
4510 papers in training set
Top 48%
2.1%
16
Journal of Translational Medicine
46 papers in training set
Top 0.7%
1.8%
17
Cancer Research
116 papers in training set
Top 2%
1.7%
18
ACS Central Science
66 papers in training set
Top 1.0%
1.7%
19
eBioMedicine
130 papers in training set
Top 2%
1.3%
20
Cancers
200 papers in training set
Top 3%
1.3%
21
PROTEOMICS
35 papers in training set
Top 0.5%
1.2%
22
eLife
5422 papers in training set
Top 49%
1.2%
23
Clinical Cancer Research
58 papers in training set
Top 1%
1.1%
24
Clinical Proteomics
10 papers in training set
Top 0.2%
0.8%
25
Journal of Proteome Research
215 papers in training set
Top 2%
0.8%
26
Nature Methods
336 papers in training set
Top 6%
0.7%
27
The Journal of Pathology
22 papers in training set
Top 0.5%
0.7%
28
Breast Cancer Research
32 papers in training set
Top 0.6%
0.7%
29
Molecular Cancer
14 papers in training set
Top 1%
0.7%
30
Endocrinology
38 papers in training set
Top 0.7%
0.7%